Thursday’s Top Biotech & Medical Stocks
by H.S. AyoubBioHealth Investor.com Biotechnology NOVAVAX INC +9.49% REXAHN PHARMACEUTICL +6.67% HESKA CORPORATION +6.57% HOLLIS-EDEN PHARM +6.34% HEMOBIOTECH INC +5.79% Diagnostic Substances MONOGRAM BIOSCIENCES +9.47% SCOLR PHARMA INC +6.42% EPICEPT CORPORATION +5.07% AVALON PHARMACEUTIC +3.95% INTERLEUKIN GENETICS +3.60% Drug Delivery…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
by H.S. Ayoub
BioHealth Investor.com
Biotechnology
NOVAVAX INC [NVAX] +9.49%
REXAHN PHARMACEUTICL [RXHN.OB] +6.67%
HESKA CORPORATION [HSKA] +6.57%
HOLLIS-EDEN PHARM [HEPH] +6.34%
HEMOBIOTECH INC [HMBT.OB] +5.79%
Diagnostic Substances
MONOGRAM BIOSCIENCES [MGRM] +9.47%
SCOLR PHARMA INC [DDD] +6.42%
EPICEPT CORPORATION [EPCT] +5.07%
AVALON PHARMACEUTIC [AVRX] +3.95%
INTERLEUKIN GENETICS [ILI] +3.60%
Drug Delivery
NSITE VISION INC [ISV] +6.21%
COLUMBIA LABS INC [CBRX] +3.45%
BIOVAIL CORP [BVF] +2.33%
IOMED INC [IOX] +1.01%
MATRIXX INITIATVS [MTXX] +0.68%
Drug Manufacturers
AMARIN CORP PLC AD [AMRN] +21.04%
SCHERING PLOUGH CP [SGP] +8.58%
SINOVAC BIOTECH LTD [SVA] +8.12%
ARENA PHARMACEUTIC [ARNA] +7.93%
EXEGENICS INC [EXEG.OB] +7.14%
Drug Related Products
XELR8 HOLDINGS, INC [BZI] +4.76%
LABOPHARM INC. [DDSS] +0.64%
Generic Drugs
CATALYST PHARMACEUTI [CPRX] +7.01%
HI-TECH PHARMACAL [HITK] +4.46%
PHARMACUTICAL CO [PRX] +0.82%
BARR PHARMA INC [BRL] +0.51%
MYLAN LABS INC [MYL] +0.09%
Medical Appliances & Equipment
MEDICAL SOLUTION MGT [MSMT.OB] +11.01%
SPECTRASCIENCE NEW [SCIE.OB] +8.00%
MEDICALCV INC [MCVI.OB] +6.67%
ST. JUDE MEDICAL [STJ] +5.47%
QMED INC [QMED] +3.51%
Medical Instruments & Supplies
I FLOW CP [IFLO] +13.17%
UROPLASTY INC [UPI] +9.13%
ICU MEDICAL INC [ICUI] +6.37%
VYTERIS HOLDINGS NV [VYHN.OB] +4.39%
FOXHOLLOW TECH INC [FOXH] +4.14%
Medical Laboratories & Research
MEDTOX SCIENTFIC INC [MTOX] +3.71%
ARRAY BIOPHARMA IN [ARRY] +3.62%
PHARM PROD DEV [PPDI] +2.58%
SPHERIX INC [SPEX] +1.67%
ENZO BIOCHEM INC [ENZ] +0.83%
Contact [email protected] for any questions or corrections.
Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.
McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.
His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.
A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.
TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.
McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.